On February 17, 2025, Cygnus Bio unveiled its Product Line P gene sequencing products and the OpenSeq Project at a new product launch event. Product Line P consists of the GP1000 (P1000) Sequencing System and the GP1000X (P1000X) Sequencing System, delivering a sequencing throughput range from 0.3Tb to 40Tb. The launch of these innovative products not only fills a critical gap in Cygnus Bio’s product portfolio but also provides the industry with more efficient and cost-effective sequencing solutions, strongly advancing the widespread application of gene sequencing technology across all sectors.
The GP1000 (P1000) Sequencing System is a fully proprietary high-throughput sequencing platform independently developed by Cygnus Bio, integrating five core technological breakthroughs: LumoSeq sequencing chemistry, artificial intelligence‑guided polymerase directed evolution, AttoSeal microfluidic manipulation, a high‑resolution wide‑bandwidth scanning imaging system, and a high‑precision deep learning base‑calling algorithm.
Among them, LumoSeq sequencing chemistry employs a novel class of nucleotide molecules. Through their unique fluorescent on‑off switching property, four nucleotide bases can be identified using only single‑color fluorescence, with no molecular scars left on DNA strands. This feature not only simplifies instrument design but also eliminates cumbersome procedures such as balanced library preparation, enabling broader application adaptability. AttoSeal microfluidic technology enables precise fluid control over attoliter‑scale (10⁻¹⁸ L) microreactors, allowing parallel and synchronous sequencing biochemical reactions across nearly 10 billion microreactors. This drastically reduces sequencing reagent consumption and achieves a leapfrog reduction in sequencing costs.
The GP1000 (P1000) Sequencing System features a dual‑chip stage design. Two reagent formats are introduced, delivering maximum data outputs of 1Tb and 2Tb respectively, with sequencing quality achieving Q40 scores above 85%. The instrument supports continuous loading, multi‑timepoint data output, and configurable sequencing workflows to accommodate flexible operational needs across diverse scenarios. It offers user‑friendly operation, with chip loading completed within 15 minutes, and is equipped with automatic multi‑channel in‑situ loading to minimize operational errors and time waste.
Thanks to LumoSeq technology, the Product Line P platform requires no balanced libraries, improving chip data utilization efficiency. It also supports sample indexing with as few as one index sequence per run, imposing extremely low restrictions on library pooling.
During the launch, Cygnus Bio also introduced the GP1000X Sequencing System. Designed in a clustered array configuration, it delivers a maximum single‑run throughput of up to 40Tb. Paired with an automated sample processing workstation and high‑performance computing and storage clusters, the system can perform up to 80,000 whole‑genome sequencing (WGS) tests per year. Significantly, the system incorporates Cygnus Bio’s newly developed chip reset technology, which sharply reduces sequencing costs and enables $50 human whole‑genome sequencing at 30× depth, greatly accelerating the accessibility and application of gene sequencing.
Product Line P has undergone real‑world testing across multiple fields, demonstrating exceptional sequencing quality and versatile applicability. At equivalent raw sequencing data volumes, the platform yields lower duplicate read rates and more uniform genome coverage, generating more usable information. These results collectively reflect the platform’s high quality, functional completeness, versatility, and ease of use.
Dr. Zitian Chen , CEO of Cygnus Bio, stated: “The introduction of the GP1000 Sequencing System and GP1000X Sequencing System not only enriches Cygnus Bio’s product lineup but also provides users with more choices and more comprehensive solutions.” He added: “The company will continue to increase R&D investment and roll out products covering a wider range of throughputs to meet the needs of different customers and scenarios. Cygnus Bio will deliver full‑scope solutions in both sequencing depth and breadth.”
Dr. Shuo Qiao , CTO of Cygnus Bio, noted: “For researchers, the most meaningful pursuit is not only to create ingenious inventions but to turn those inventions into practical solutions for users and new productivity for the entire industry. We believe that high‑quality data and greatly improved cost‑performance driven by fundamental innovation will open up new possibilities for users and realize true sequencing freedom.”
To foster continued innovation and expanded application of gene sequencing technology, Cygnus Bio also launched the OpenSeq Project, which provides 1 million gigabytes of sequencing resources. The initiative aims to offer researchers an open gene sequencing platform, granting access to free sequencing resources as well as innovative services including custom on‑chip primers and customizable sequencing modes.
Moving forward, Cygnus Bio will uphold an innovation‑driven strategy and remain committed to independent research and development. By increasing scientific investment, the company will continuously strengthen its technical capabilities and innovation, enhance sequencer performance and user experience, ensure high‑quality data output, and pursue lower sequencing costs to promote the inclusive application of gene sequencing technology.
Cygnus Bio will provide simpler, more accurate, and more efficient gene sequencing tools and solutions for life science sectors including biological research, medical diagnosis, drug development, animal and plant breeding, customs inspection, disease control, and forensic science. It will offer robust technical support for scientific research and clinical practice, contributing to the improvement of public health.
